Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Rhythm Pharmaceuticals, Inc. - Common Stock
(NQ:
RYTM
)
99.42
-2.44 (-2.40%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rhythm Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
October 08, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Navigating 5 Analyst Ratings For Rhythm Pharmaceuticals
↗
October 07, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals
↗
September 18, 2024
Via
Benzinga
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
September 16, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts
↗
July 25, 2024
Via
Benzinga
Analyst Expectations For Rhythm Pharmaceuticals's Future
↗
April 26, 2024
Via
Benzinga
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
August 26, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
August 26, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
August 13, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
RYTM Stock Earnings: Rhythm Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024
↗
August 06, 2024
RYTM stock results show that Rhythm Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
August 06, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
July 31, 2024
IMCIVREE now authorized as treatment of obesity and control of hunger in adult patients and pediatric patients 2 years old or older with Bardet Biedl syndrome or POMC, PCSK1, or LEPR deficiency
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
July 23, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
July 23, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
July 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
July 08, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
June 28, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
June 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
June 03, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
June 03, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
May 22, 2024
IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centres
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
May 09, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
The 3 Best Nasdaq Stocks to Buy in May 2024
↗
May 07, 2024
Although it’s typically the season for selling, shifting market conditions call for the best Nasdaq stocks to buy in May.
Via
InvestorPlace
RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
↗
May 07, 2024
RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
May 07, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
May 06, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
April 29, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
April 24, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson
↗
April 19, 2024
The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest.
Via
Benzinga
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
April 16, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
